Peritoneal metastasis (PM) occurs in approximately one in four colorectal cancer (CRC) patients. The pathophysiology of colorectal PM remains poorly characterized. Also, the efficacy of current treatment modalities, including surgery and intraperitoneal (IP) delivery of chemotherapy, is limited. Increasingly, therefore, efforts are being developed to unravel the PM cascade and at understanding the PM-associated tumor microenvironment (TME) and peritoneal ecosystem as potential therapeutic targets. Here, we review recent insights in the structure and components of the TME in colorectal PM, and discuss how these may translate into novel therapeutic approaches aimed at re-engineering the metastasis-promoting activity of the stroma.

大约四分之一的大肠癌（CRC）患者发生腹膜转移（PM）。大肠PM的病理生理学仍不明确。而且，包括手术和腹膜内（IP）化学疗法在内的当前治疗方式的功效是有限的。因此，越来越多的人致力于解开PM级联，并了解PM相关的肿瘤微环境（TME）和腹膜生态系统作为潜在的治疗靶标。在这里，我们回顾了对结直肠PM中TME的结构和成分的最新见解，并讨论了这些可能如何转化为旨在重新设计基质转移促进活性的新型治疗方法。